<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131429</url>
  </required_header>
  <id_info>
    <org_study_id>PLAGH-TKIs</org_study_id>
    <nct_id>NCT01131429</nct_id>
  </id_info>
  <brief_title>A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations</brief_title>
  <official_title>Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: the objective of this study in china is to clarify, whether the overall survival
      is different between previously untreated stage IIIB/IV lung adenocarcinoma with EGFR
      mutations receiving first-line erlotinib plus second-line docetaxel/cisplatin and those
      receiving first-line docetaxel/cisplatin plus second-line erlotinib .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>three year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival during the first-line treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free time during the second-line treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during the first-line therapy</measure>
    <time_frame>every 3 weeks during first-line therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during the second-line therapy</measure>
    <time_frame>every 3 weeks during the second-line therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rates during the first-line treatment</measure>
    <time_frame>at 6 months from treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rates during the second-line treatment</measure>
    <time_frame>every 3 weeks during the treament, and and every 6 weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity during the first-line treatment</measure>
    <time_frame>at 12 months from treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity during the second-line treatment</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preditive and prognostic markers for chemotherapy or erlotinib</measure>
    <time_frame>end of study</time_frame>
    <description>tissues for markers analysis are acquired during diagnosis procedure with informed consent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neoplasms, Lung</condition>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <condition>Drug Therapy</condition>
  <condition>Genes, EGFR</condition>
  <arm_group>
    <arm_group_label>first-line erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erlotinib in first-line treatment and docetaxel/cisplatin in second-line treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>second-line erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel/cisplatin in first-line treatment and erlotinib in second-line treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg/d per os until proven disease progression</description>
    <arm_group_label>first-line erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment</description>
    <arm_group_label>first-line erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment</description>
    <arm_group_label>first-line erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most</description>
    <arm_group_label>second-line erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most</description>
    <arm_group_label>second-line erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg/d per os as second-line treatment</description>
    <arm_group_label>second-line erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged over 18 years

          -  Histologically proven lung adenocarcinoma

          -  clinical stage IIIB/IV

          -  ECOG performance status 0-2

          -  Had no prior anticancer agent, radiation or surgical therapy for lung adenocarcinoma

          -  At least one measurable lesion (according to RECIST)

          -  Provision of written informed consent

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  History of malignant disease.

          -  Evidence of clinically active interstitial lung diseases (patients with chronic,
             stable, radiographic changes who are asymptomatic need not be excluded)

          -  Expected life expectancy less than 2 months

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)

          -  Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 2.5 x
             ULN if no demonstrable liver metastases (or &gt;5 x in presence of liver metastases)

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the study

          -  Pregnancy or breast-feeding women (women of child¬bearing potential). Women of
             childbearing potential must practice acceptable methods of birth control to prevent
             pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang-An Chen, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liang-An Chen, MD, phD</last_name>
    <phone>86-10-66939361</phone>
    <email>chenla301@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liang-An Chen, MD, phD</last_name>
      <phone>86-10-66939361</phone>
      <email>chenla301@263.net</email>
    </contact>
    <investigator>
      <last_name>Liang-An Chen, MD, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Liang-An Chen, M.D., Ph.D</name_title>
    <organization>Chinese PLA General Hospital, Beijing, China</organization>
  </responsible_party>
  <keyword>mutation analysis</keyword>
  <keyword>first-line</keyword>
  <keyword>second-line</keyword>
  <keyword>targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

